Q/C Technologies, Inc. — Company profile
Technology · Computer Hardware · United States
Last price 0.4404 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.61M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Details
| Name | Q/C Technologies, Inc. |
| Sector | Technology |
| Industry | Computer Hardware |
| Employees | 3 |
| Founded | 2014 |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US62856X3008 |
| Cusip | 62856X300 |
| Cik | 0001321834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Joshua N. Silverman | Executive Chairman of the Board |
| Ian Thomas Rhodes CPA | Chief Financial Officer |
| Dr. Mitchell Glass M.D. | Chief Medical Officer and Director |
| Yossef Ehrlichman | Chief Technology Officer |
| Robert Schatz | Investor Relations Officer |
Contact
| Address | 1185 Avenue of the Americas, Suite 249, New York, New York 10036, United States |
| Phone | 856 848 8698 |
| Website | https://www.qctechnologies.com |